CN101448819A - (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体 - Google Patents

(5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体 Download PDF

Info

Publication number
CN101448819A
CN101448819A CNA2007800178360A CN200780017836A CN101448819A CN 101448819 A CN101448819 A CN 101448819A CN A2007800178360 A CNA2007800178360 A CN A2007800178360A CN 200780017836 A CN200780017836 A CN 200780017836A CN 101448819 A CN101448819 A CN 101448819A
Authority
CN
China
Prior art keywords
methyl
imidazolidine
chloro
compound
diketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800178360A
Other languages
English (en)
Chinese (zh)
Inventor
尼尔·巴恩韦尔
拉尔斯-埃里克·布里格纳
安德烈亚·科尔
安德斯·埃里克森
雅各布·珀金斯
鲁伊斯-曼纽尔·瓦兹
安德鲁·韦尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38509897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101448819(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101448819A publication Critical patent/CN101448819A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA2007800178360A 2006-03-16 2007-03-15 (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体 Pending CN101448819A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78297906P 2006-03-16 2006-03-16
US60/782,979 2006-03-16

Publications (1)

Publication Number Publication Date
CN101448819A true CN101448819A (zh) 2009-06-03

Family

ID=38509897

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800178360A Pending CN101448819A (zh) 2006-03-16 2007-03-15 (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体

Country Status (16)

Country Link
US (1) US20090221640A1 (enExample)
EP (1) EP2064202A4 (enExample)
JP (1) JP2009531313A (enExample)
KR (1) KR20090008229A (enExample)
CN (1) CN101448819A (enExample)
AR (1) AR059913A1 (enExample)
AU (1) AU2007225477A1 (enExample)
BR (1) BRPI0709579A2 (enExample)
CA (1) CA2644345A1 (enExample)
CL (1) CL2007000680A1 (enExample)
IL (1) IL193670A0 (enExample)
MX (1) MX2008011641A (enExample)
NO (1) NO20084282L (enExample)
TW (1) TW200800954A (enExample)
UY (1) UY30214A1 (enExample)
WO (1) WO2007106022A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
CN117820178A (zh) * 2023-12-26 2024-04-05 山东泰和科技股份有限公司 一种d,l-蛋氨酸的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CA2815460C (en) * 2011-01-13 2017-04-18 Bio-Pharm Solutions Co., Ltd. Process for preparation of phenyl carbamate derivatives
EP2797878B1 (en) 2011-12-27 2017-08-16 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
WO2014178433A1 (ja) 2013-05-02 2014-11-06 株式会社エーピーアイ コーポレーション α－置換システインもしくはその塩又はα－置換システイン合成中間体の製造方法
CN116033902A (zh) 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172762A (ja) * 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
GB8618559D0 (en) * 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) * 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) * 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
NL9201230A (nl) * 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
TW514634B (en) * 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
PL364714A1 (en) * 2001-03-15 2004-12-13 Astrazeneca Ab Metalloproteinase inhibitors
MXPA04010845A (es) * 2002-04-30 2005-01-25 Biogal Gyogyszergyar Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
KR20040106518A (ko) * 2002-05-10 2004-12-17 테바 파마슈티컬 인더스트리즈 리미티드 가티플록사신의 신규한 결정 형태
EP2287152B1 (en) * 2002-06-05 2015-01-14 Kaneka Corporation Process for producing optically active alpha-methylcysteine derivative
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
CN117820178A (zh) * 2023-12-26 2024-04-05 山东泰和科技股份有限公司 一种d,l-蛋氨酸的制备方法

Also Published As

Publication number Publication date
US20090221640A1 (en) 2009-09-03
MX2008011641A (es) 2008-09-22
CL2007000680A1 (es) 2008-02-08
UY30214A1 (es) 2007-10-31
WO2007106022A3 (en) 2007-11-01
BRPI0709579A2 (pt) 2011-07-19
WO2007106022A2 (en) 2007-09-20
AR059913A1 (es) 2008-05-07
EP2064202A2 (en) 2009-06-03
JP2009531313A (ja) 2009-09-03
NO20084282L (no) 2008-10-13
KR20090008229A (ko) 2009-01-21
EP2064202A4 (en) 2011-01-12
IL193670A0 (en) 2009-05-04
CA2644345A1 (en) 2007-09-20
AU2007225477A1 (en) 2007-09-20
TW200800954A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
CN101448819A (zh) (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体
EP2649060B1 (en) Process for the preparation of benzimidazole derivatives and its salts
KR101651288B1 (ko) 4-메틸-ｎ-［3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸페닐］-3-(4-피리딘-3-일-피리미딘-2-일아미노)벤즈아미드의 결정 형태
EP2716642B1 (en) Imidazopyridine compound
US9643927B1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
HUT74103A (en) Aroyl-piperidine derivative
CN1129941A (zh) 取代的氮杂二氢亚吲哚基化合物及其制备方法
CN102164920B (zh) 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途
US10550087B2 (en) Process for the preparation of kinase inhibitors and intermediates thereof
TW201202198A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
KR20000005505A (ko) 피페리딘 및 피롤리딘
EP3492452B1 (en) Production method for pyrazole-amide compound
CN101163684A (zh) 具有酪氨酸激酶抑制作用的喹唑啉衍生物
WO2020153434A1 (ja) ピラゾール化合物
US20210323946A1 (en) Process for preparing a phthalazinone derivative and intermediates thereof
US20140336211A1 (en) Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-Indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl ] -amide
JP2012519680A (ja) ジヒドロベンゾオキサゾール−６−イル−アセトアミド誘導体の新規結晶性水和物、非晶質体、多形体およびその調製プロセス
EP3199534B1 (en) Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
EP4357335A1 (en) Azabicyclo[3.1.0]hexane compound
TW201329087A (zh) 胜肽脫甲醯酶抑制劑
TW201336838A (zh) ２－（２－甲基胺基－嘧啶－４－基）－１ｈ－吲哚－５－羧酸［（ｓ）－１－胺甲醯基－２－（苯基－嘧啶－２－基－胺基）－乙基］－醯胺之結晶型
CZ20002242A3 (cs) Způsoby a meziprodukty pro výrobu 3(S)-[(5-chlor-1H-indol-2-karbonyl)-amino]-2(R)-hydroxy-4-fenylmáselné kyseliny

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090603